Filing Flows › Industries › Pharmaceutical Preparations › Capital spending and supply chain
Pharmaceutical Preparations: capital spending and supply chain
SIC 2834 · 169 companies with filed cash-flow statements
Capital spending, 12 months$33.3B
Operating cash flow$145.5B
Capex / cash flow23%
Capex / revenue5.1%
Top 3 share62%
Analysis
169 companies in Pharmaceutical Preparations (SIC 2834) spent $33.3B on capital projects over their latest twelve months, 23% of the $145.5B their operations generated; the three largest spenders — LLY, JNJ, MRK — account for 62%.
Capital spending is 5.1% of the industry's $648.0B of annual revenue.
By the industry's asset mix most of it goes to equipment (44%); about $5.1B is imported.
The largest supplier of that spending is manufacturing structures ($8.4B).
Its largest supplying industries, by the input-output tables: imports ($77.8B), drugs and druggists' sundries ($53.9B), biological product (except diagnostic) manufacturing ($40.1B).
Charts
Capital spending by company
| Company | Capital spending | Operating cash flow | Capex / OCF | Period |
|---|---|---|---|---|
| LLY ELI Lilly | $11.0B | $30.6B | 36% | TTM to Q3 2026 |
| JNJ Johnson & Johnson | $5.6B | $26.2B | 21% | TTM to Q3 2026 |
| MRK Merck | $4.0B | $18.7B | 21% | TTM to Q3 2026 |
| PFE Pfizer | $2.4B | $14.2B | 17% | TTM to Q3 2026 |
| ABT Abbott Laboratories | $2.1B | $8.9B | 24% | TTM to Q3 2026 |
| BMY Bristol Myers Squibb | $1.4B | $10.7B | 13% | TTM to Q3 2026 |
| ABBV AbbVie | $1.2B | $20.1B | 6% | TTM to Q3 2026 |
| REGN Regeneron Pharmaceuticals | $1.0B | $4.8B | 21% | TTM to Q3 2026 |
| UTHR United Therapeutics | $562M | $1.4B | 39% | TTM to Q3 2026 |
| TEVA Teva Pharmaceutical Industries | $535M | $1.8B | 30% | TTM to Q3 2026 |
| ZTS Zoetis | $493M | $2.7B | 18% | TTM to Q3 2026 |
| VRTX Vertex Pharmaceuticals | $492M | $3.7B | 13% | TTM to Q3 2026 |
| VTRS Viatris | $375M | $2.5B | 15% | TTM to Q3 2026 |
| BHC Bausch Health Companies | $344M | $2.2B | 16% | TTM to Q3 2026 |
| ELAN Elanco Animal Health | $206M | $614M | 34% | TTM to Q3 2026 |
| OGN Organon | $168M | $843M | 20% | TTM to Q3 2026 |
| ALNY Alnylam Pharmaceuticals | $150M | $956M | 16% | TTM to Q3 2026 |
| VREOF Vireo Growth | $143M | $26.2M | 544% | TTM to Q2 2026 |
| ONC BeOne Medicines | $141M | $1.6B | 9% | TTM to Q3 2026 |
| BMRN BioMarin Pharmaceutical | $119M | $677M | 18% | TTM to Q3 2026 |
| AMRX Amneal Pharmaceuticals | $72.9M | $201M | 36% | TTM to Q2 2026 |
| PRGO Perrigo | $72.4M | $241M | 30% | TTM to Q3 2026 |
| JAZZ Jazz Pharmaceuticals | $70.8M | $1.7B | 4% | TTM to Q3 2026 |
| INDV Indivior Pharmaceuticals | $65.0M | $96.0M | 68% | TTM to Q3 2026 |
| IONS Ionis Pharmaceuticals | $64.4M | −$496M | — | TTM to Q2 2026 |
| PAHC Phibro Animal Health | $64.1M | $85.7M | 75% | TTM to Q1 FY27 |
| Keenova Therapeutics | $47.6M | $245M | 19% | TTM to Q2 2026 |
| AMPH Amphastar Pharmaceuticals | $36.3M | $175M | 21% | TTM to Q3 2026 |
| INSM Insmed | $32.0M | −$596M | — | TTM to Q3 2026 |
| CYRX Cryoport | $29.8M | $11.0M | 271% | TTM to Q3 2026 |
| ABCL AbCellera Biologics | $24.7M | −$94.9M | — | TTM to Q2 2026 |
| ANIP ANI Pharmaceuticals | $23.9M | $229M | 10% | TTM to Q3 2026 |
| LQDA Liquidia | $17.0M | $168M | 10% | TTM to Q2 2026 |
| OCUL Ocular Therapeutix | $16.9M | −$238M | — | TTM to Q2 2026 |
| CYTK Cytokinetics | $16.6M | −$572M | — | TTM to Q3 2026 |
| ARWR Arrowhead Pharmaceuticals | $16.1M | −$59.1M | — | TTM to Q3 FY26 |
| ALKS Alkermes | $15.6M | $243M | 6% | TTM to Q3 2026 |
| PBH Prestige Consumer Healthcare | $15.6M | $230M | 7% | TTM to Q2 FY27 |
| ACAD Acadia Pharmaceuticals | $15.5M | $97.5M | 16% | TTM to Q3 2026 |
| MNKD Mannkind | $12.2M | −$66.2M | — | TTM to Q3 2026 |
| EBS Emergent BioSolutions | $11.7M | $200M | 6% | TTM to Q3 2026 |
| MDGL Madrigal Pharmaceuticals | $11.6M | −$157M | — | TTM to Q3 2026 |
| CAPR Capricor Therapeutics | $10.9M | −$104M | — | TTM to Q2 2026 |
| ORGO Organogenesis Holdings | $10.4M | $10.3M | 101% | TTM to Q3 2026 |
| IMNM Immunome | $10.3M | −$209M | — | TTM to Q2 2026 |
| OPK Opko Health | $10.3M | −$125M | — | TTM to Q3 2026 |
| NRIX Nurix Therapeutics | $9.5M | $379M | 3% | TTM to Q3 FY26 |
| SRPT Sarepta Therapeutics | $9.2M | $186M | 5% | TTM to Q3 2026 |
| NATR Natures Sunshine Products | $9.1M | $19.6M | 46% | TTM to Q3 2026 |
| PTCT PTC Therapeutics | $8.4M | $10.5M | 80% | TTM to Q3 2026 |
| MRVI Maravai Lifesciences Holdings | $8.2M | −$5.1M | — | TTM to Q3 2026 |
| PCRX Pacira BioSciences | $7.9M | $177M | 4% | TTM to Q3 2026 |
| KURA Kura Oncology | $5.7M | −$112M | — | TTM to Q2 2026 |
| STOK Stoke Therapeutics | $5.4M | −$210M | — | TTM to Q3 2026 |
| TNXP Tonix Pharmaceuticals Holding | $5.1M | −$153M | — | TTM to Q2 2026 |
| ABEO Abeona Therapeutics | $5.1M | −$76.4M | — | TTM to Q2 2026 |
| RARE Ultragenyx Pharmaceutical | $5.0M | −$437M | — | TTM to Q3 2026 |
| ROIV Roivant Sciences | $4.6M | −$816M | — | TTM to Q1 FY27 |
| AGIO Agios Pharmaceuticals | $4.3M | −$332M | — | TTM to Q3 2026 |
| SDGR Schrodinger | $4.2M | −$113M | — | TTM to Q3 2026 |
Customers and suppliers named in annual reports
| Supplier | Customer | Share of supplier revenue | Evidence | Source |
|---|---|---|---|---|
| BMY | MCK | 36% | Stated in 10-K (XBRL) | filing |
| PFE | MCK | 25% | Stated in 10-K (XBRL) | filing |
| BMY | COR | 29% | Stated in 10-K (XBRL) | filing |
| BMY | CAH | 22% | Stated in 10-K (XBRL) | filing |
| PFE | COR | 16% | Stated in 10-K (XBRL) | filing |
| PFE | CAH | 13% | Stated in 10-K (XBRL) | filing |
| BHC | COR | 18% | Stated in 10-K (customer table) | filing |
| BHC | MCK | 16% | Stated in 10-K (customer table) | filing |
| BHC | CAH | 14% | Stated in 10-K (customer table) | filing |
| ONC | MCK | 18% | Stated in 10-K (XBRL) | filing |
| ALNY | NVS | 23% | Stated in 10-K (customer table) | filing |
| Keenova Therapeutics plc | COR | 48% | Stated in 10-K (customer table) | filing |
| Keenova Therapeutics plc | FFF Enterprises, Inc | 46% | Stated in 10-K (XBRL) | filing |
| ELAN | COR | 12% | Stated in 10-K (sentence) | filing |
| ALKS | MCK | 38% | Stated in 10-K (sentence) | filing |
| PRGO | WMT | 12% | Stated in 10-K (sentence) | filing |
| ALKS | Mc Kesson Corporation | 31% | Stated in 10-K (XBRL) | filing |
| JAZZ | MCK | 10% | Stated in 10-K (customer table) | filing |
| ALNY | REGN | 11% | Stated in 10-K (customer table) | filing |
| HRMY | CVS | 38% | Stated in 10-K (sentence) | filing |
| HRMY | Accredo Health Group, Inc | 36% | Stated in 10-K (XBRL) | filing |
| IRWD | ABBV | 99% | Stated in 10-K (XBRL) | filing |
| ALKS | COR | 18% | Stated in 10-K (sentence) | filing |
| HRMY | PANTHERx Specialty Pharmacy LLC | 26% | Stated in 10-K (XBRL) | filing |
| PCRX | MCK | 31% | Stated in 10-K (sentence) | filing |
| ALKS | CAH | 15% | Stated in 10-K (sentence) | filing |
| PBH | WMT | 20% | Stated in 10-K (sentence) | filing |
| PCRX | CAH | 26% | Stated in 10-K (sentence) | filing |
| ITGR | ABT | 10% | Stated in 10-K (sentence) | filing |
| AMPH | MCK | 24% | Stated in 10-K (XBRL) | filing |
| PBH | AMZN | 15% | Stated in 10-K (sentence) | filing |
| PCRX | COR | 22% | Stated in 10-K (sentence) | filing |
| AMPH | COR | 22% | Stated in 10-K (XBRL) | filing |
| AMPH | CAH | 19% | Stated in 10-K (XBRL) | filing |
| RIGL | MCK | 42% | Stated in 10-K (customer table) | filing |
| EXEL | RPRX | 3% | Stated in 10-K (sentence) | filing |
| GYRE | Sinopharm Group Company Limited | 52% | Stated in 10-K (XBRL) | filing |
| AKBA | DVA | 25% | Stated in 10-K (customer table) | filing |
| ANIK | JNJ | 50% | Stated in 10-K (sentence) | filing |
| RIGL | COR | 19% | Stated in 10-K (customer table) | filing |
The interactive money flow: switch views, follow each dollar →
Evidence grades: A filed figure · B computed from filed figures · C industry average (BEA input-output and fixed-asset tables) applied to filed figures. Estimates are not the companies’ own records. Not investment advice.